Want to join the conversation?
$LH 2Q15 Call: For Covance drug development, revenue for quarter was $644MM, a decrease of 2.7% from last year. Strengthening USD negatively impacted revenue growth by approx. 450BP. On a constant currency basis, revenue increased 1.8% over last year, due to volume growth, partially offset by unfavorable mix.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.